US Patent

US8652527 — Extended-release topiramate capsules

Formulation · Assigned to Upsher Smith Laboratories LLC · Expires 2033-03-19 · 7y remaining

Vulnerability score 47/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an extended-release topiramate capsule with a coating that controls the release of topiramate.

USPTO Abstract

An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Drugs covered by this patent

Patent Metadata

Patent number
US8652527
Jurisdiction
US
Classification
Formulation
Expires
2033-03-19
Drug substance claim
No
Drug product claim
Yes
Assignee
Upsher Smith Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.